comparemela.com

Latest Breaking News On - Clinical lung - Page 1 : comparemela.com

Identifying EGFR-Mutant Lung Cancer Patients Who Will Benefit From Immune Checkpoint Inhibitors

Identifying EGFR-Mutant Lung Cancer Patients Who Will Benefit From Immune Checkpoint Inhibitors
cancertherapyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cancertherapyadvisor.com Daily Mail and Mail on Sunday newspapers.

Targeted Therapy Provides Greatest OS Benefit if Started Within 1 Month of NSCLC Diagnosis

Targeted Therapy Provides Greatest OS Benefit if Started Within 1 Month of NSCLC Diagnosis
oncologynurseadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oncologynurseadvisor.com Daily Mail and Mail on Sunday newspapers.

Targeted Therapy Provides Greatest OS Benefit if Started Within 1 Month of NSCLC Diagnosis

A new study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell lung cancer diagnosis can still improve overall survival, when compared to other first-line therapies. Starting a patient on preferred targeted therapy within 1 year of metastatic NSCLC diagnosis can still improve overall survival, when compared to other therapies.

Clinical lung

Machine-Learning Models May Help Determine Brain Metastasis Risk in Patients With NSCLC

Patients with non-small cell lung cancer (NSCLC) with a high risk of brain metastases might feasibly be identified through machine-learning models, according to a recent study.

Clinical lungCorrelation coefficientLung cancerNon small cell lung cancerBrain metastasesSquamous cell carcinoma

Transforming oncology with antibody therapeutics

Janssen EMEA Therapeutic Area Lead for Oncology discusses the potential of BsMAbs like amivantamab to address unmet needs in NSCLC treatment.

Byoung chulMartin vogelJanssen europePersonalized medicine coalitionEuropean lung cancer congressDrug administrationTherapeutic area leadTherapeutic area lead oncologyEpidermal growth factor receptorMesenchymal epithelial transition factorBispecific antibodyEnable multiple mechanismsBroad clinicalClinical lung

vimarsana © 2020. All Rights Reserved.